New research by Alpharmaxim applies behavioural science to identify and understand prescribing choices in neurogenerative diseases – and highlights the need to optimise them
ALTRINCHAM, England, July 3, 2025 /PRNewswire/ — A groundbreaking new study, published in PLOS One, has uncovered key behavioural factors influencing how medications are prescribed to people living with neurodegenerative diseases. The findings raise important questions about clinical decision-making, and the need for more targeted strategies in managing complex neurological conditions, including Parkinson’s Disease. Conducted by








